Please login to the form below

Not currently logged in
Email:
Password:

Questcor

This page shows the latest Questcor news and features for those working in and with pharma, biotech and healthcare.

US piles pressure on Mallinckrodt over alleged Acthar fraud

US piles pressure on Mallinckrodt over alleged Acthar fraud

The NDA approval was awarded to Acthar’s earlier owner Questcor, which was acquired by Mallinckrodt for $5.6bn in 2014.

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    wholesale takeovers with deals in Devices (Biomet/ Zimmer Holdings, AccessClosure/ Cardinal Health; New Wave Surgical/ Covidien), Generics/ Speciality Pharma (Questcor/ Mallinckrodt, Ranbaxy Laboratories/ Sun Pharmaceuticals; Silom Medical Company/

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    165. Novartis / Questcor. Development rights. Rights to develop Synacthen (tetracosactide,   melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune &inflammatory conditions).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Questcor appoints SVP corporate strategic development Questcor appoints SVP corporate strategic development

    Michael Aldridge joins from Australian early development company Xenome. US biopharma Questcor Pharmaceuticals has named Michael Aldridge as its first senior VP, corporate strategic development. ... Development programmes that complement Acthar are also

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...